Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 14/20 | 0.39 |
| ▸ | CTSL | P07711 | 8/20 | 0.39 |
| ▸ | CTSB | P07858 | 6/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6749700 | 0.80 | CTSS (0.42) | CTSSCTSLCTSBMETAP2METAP1 | |
| SCHEMBL6700232 | 0.77 | METAP2 (0.35) | CTSSCTSLMETAP2METAP1 | |
| SCHEMBL6295607 | 0.73 | OPRK1 (0.31) | — | |
| SCHEMBL5870430 | 0.72 | CTSS (0.42) | CTSSCTSLCTSBMETAP2METAP1 | |
| SCHEMBL4451525 | 0.72 | EPHX2 (0.46) | CTSSCTSLCTSBMETAP2METAP1 | |
| SCHEMBL6300518 | 0.72 | ALDH1A1 (0.38) | CTSSMETAP2METAP1 | |
| SCHEMBL6300240 | 0.72 | OPRK1 (0.32) | — | |
| SCHEMBL9265345 | 0.71 | SLC1A3 (0.45) | CTSSCTSLCTSBMETAP2METAP1 | |
| SCHEMBL6062939 | 0.71 | CTSS (0.57) | CTSSCTSLCTSBCTSK | |
| SCHEMBL6702132 | 0.70 | GRIA2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958358-B2 | administering a cystatin; 4-tert-Butyl-N-[2-(4-hydroxyphenyl)-1S-(3-oxo-hexahydrocyclopenta[b]furan-3a-ylcarbamoyl)-ethyl]benzamide; bioassay for validation of efficacy ; Chagas' disease; parasiticide, trypanocide | AMURA THERAPEUTICS LIMITED (GB) | 2005-10-25 | — | — | US | disclosed |
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-06-03 | — | — | US | disclosed |
| EP-1358176-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002057246-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | CTRL, CPN1, CPA1 | CTSS 19/4885CTSL 15/4885CTSB 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.